Current Projects

"Novel Protein Translation Inhibitor Augments Epigenetic Therapy for Pancreatic Cancer"

Lead Investigator: Susan Bates, MD

Susan E. Bates, MD

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and one of the deadliest, with approximately 85–90% of patients dying within five years of diagnosis. Treatment options remain limited, and many tumors develop resistance to existing therapies. The Bates lab is developing a new treatment approach that combines two types of drugs to disrupt processes that cancer cells depend on for growth and survival. The first blocks eIF4A, a protein involved in producing other proteins that cancer cells need to function. The second is a histone deacetylase (HDAC) inhibitor, which changes how DNA is packaged and helps regulate which genes are turned on or off. Researchers have found that combining these drugs produces stronger anti-cancer effects than either treatment alone, particularly in pancreatic cancers driven by a gene called MYC, which promotes uncontrolled cell growth. This approach is also effective in tumors that become resistant to newer therapies targeting KRAS, another gene commonly involved in pancreatic cancer. The team is now investigating how these drugs work together, including their effects on the processes that regulate gene activity and cancer cell metabolism. They also plan to evaluate the combination's effectiveness and potential side effects in laboratory and animal models. Their goal is to generate the evidence needed to advance this two-drug strategy toward clinical trials, offering a potential new treatment option for patients with aggressive pancreatic cancer. 

"Development of inhibitors of the SMARCAL1 DNA translocase"

Lead Investigator: Alberto Ciccia, PhD

Alberto Ciccia

Alberto Ciccia, PhD

Cancer cells must maintain the protective ends of their chromosomes, called telomeres, to continue dividing and growing. While most cancers rely on an enzyme called telomerase to maintain their telomeres, approximately 10% use a different process known as alternative lengthening of telomeres (ALT). This process is particularly common in certain cancers, including osteosarcoma and glioma, which can be difficult to treat with existing therapies. The Ciccia lab is developing a new treatment approach that targets SMARCAL1, a protein involved in DNA repair and maintenance that helps support the ALT process in certain cancer cells. By blocking SMARCAL1, researchers hope to disrupt the ability of these tumors to maintain their telomeres, limiting their growth and survival. The team has identified promising compounds that inhibit SMARCAL1 and plan to test these compounds in cancer cells, followed by preclinical studies to evaluate their ability to slow tumor growth and assess potential side effects. Their goal is to develop a targeted treatment for ALT-positive cancers, offering new options for patients with tumors that currently have limited effective therapies. 

"Treatment of STK11-deficient non-small cell lung cancer with a novel small molecule cancer immunotherapy" 

Lead Investigator: Benjamin Izar, MD, PhD

Ben Izar

Benjamin Izar, MD, PhD

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Some of these tumors have a mutation in a gene called STK11, which makes them particularly aggressive and less likely to respond to existing immunotherapies. The Izar lab is developing a new treatment approach for these difficult-to-treat cancers by targeting chromosomal instability, a condition in which cancer cells have abnormal numbers or structures of chromosomes. This instability can activate a signaling cascade that promotes cancer immune evasion, thus, propelling cancer progression. The researchers believe that blocking this cascade will restore the immune system's ability to recognize and attack STK11-deficient tumors. To test this approach, they are developing small molecule drugs and evaluate their effectiveness in biochemical, cellular, animal and patient models. Their goal is to develop a new treatment option for patients with STK11-deficient non-small cell lung cancer, with potential applications for other cancers that have high levels of chromosomal instability. 

"Bispecific Phagocyte Engagers as Anti-Amyloid Strategy"

Lead Investigator: Suzanne Lentzsch, MD, PhD

Light chain (AL) amyloidosis is a rare, life-threatening disease in which abnormal proteins, called light chains, build up in vital organs such as the heart and kidneys, gradually damaging them and potentially leading to organ failure. Patients with advanced disease have particularly poor outcomes, with the most severe cases surviving a median of just 5.8 months. Current treatments can reduce the production of these harmful proteins but generally cannot remove deposits that have already accumulated in organs. To address this challenge, the Lentzsch lab is developing a new type of treatment called bispecific phagocyte engagers (BiPEs), which are engineered antibodies designed to connect amyloid deposits directly to immune cells responsible for clearing unwanted material from the body. This approach helps immune cells recognize and remove the harmful protein buildup. In earlier laboratory studies, the team developed BiPEs targeting amyloid deposits formed by kappa light chains and found that they were more effective at promoting amyloid clearance than a previously developed antibody treatment. In addition, the researchers are expanding this approach to target lambda light chains, which are responsible for approximately 80% of AL amyloidosis cases. Using a newly developed antibody that specifically recognizes lambda light chains, they aim to create and test new BiPEs that can help clear these deposits from affected organs. Their goal is to advance this treatment toward human clinical trials and establish a strategy that could also be used to treat other diseases caused by harmful protein buildup. 

"Therapeutic targeting of cancer-associated DNA hypermethylation" 

Lead Investigators: Chao Lu, PhD

Headshot of Chao Lu, PhD

Chao Lu, PhD

Cancer cells can undergo changes that turn off genes responsible for preventing tumor growth. One way this happens is through DNA hypermethylation, a process in which chemical tags accumulate on certain regions of DNA and prevent important genes from being activated. When this occurs in tumor suppressor genes, which normally help control cell growth, cancer cells can grow and spread more easily. Although existing treatments can remove these chemical tags, they often affect DNA throughout the cell, potentially causing unwanted side effects. The Lu lab is developing a more targeted approach by focusing on two proteins, DNMT3A and histone H2A, that work together to promote DNA hypermethylation. By blocking the interaction between these proteins, researchers hope to selectively remove the chemical tags that silence tumor suppressor genes without disrupting other important cellular processes. Their goal is to develop a more precise and potentially safer treatment that restores the activity of tumor suppressor genes and slows cancer progression. 

Back to top